Speir, M.
Authier-Hall, A.
Brooks, C. R.
Farrand, K. J.
Compton, B. J.
Anderson, R. J.
Heiser, A.
Osmond, T. L.
Tang, C. W.
Berzofsky, J. A.
Terabe, M.
Painter, G. F.
Hermans, I. F.
Weinkove, R. http://orcid.org/0000-0003-3645-7988
Article History
Received: 11 May 2017
Accepted: 16 October 2017
First Online: 27 October 2017
Competing Interests
: Competing financial interests: B.J.C., R.J.A., G.F.P. and I.F.H. are inventors on patents related to the glycolipid-peptide conjugate vaccines used in this study. These patents have been licensed by a company, Avalia Immunotherapies, for commercialization. I.F.H. and G.F.P. are the founding C.S.O. and C.T.O. of Avalia Immunotherapies. T.L.O. is employed by Avalia Immunotherapies. R.W. has received compensation as a scientific advisory board member for Avalia Immunotherapies. M.S., A.A., C.R.B., K.J.F., A.H., J.A.B. and M.T. declare no potential conflicts of interest.